[feed] Atom [feed] RSS 1.0 [feed] RSS 2.0

Ghosh , S. and Dutta , N. and Banerjee, P. and Gajbhiye, RL. and Sareng, HR. and Kapse , P. and Pal, S. and Burdelya , L. and Mandal, NC. and Ravichandiran , V. and Bhattacharjee, A. and Kundu, GC. and Gudkov, AV. and Pal, M. (2021) Induction of monoamine oxidase A-mediated oxidative stress and impairment of NRF2-antioxidant defence response by polyphenol-rich fraction of Bergenia ligulata sensitizes prostate cancer cells in vitro and in vivo. Free Radical Biology and Medicine, 172. pp. 136-151.

Full text not available from this repository. (Request a copy)


Prostate cancer (PCa) is a major cause of mortality and morbidity in men. Available therapies yield limited outcome. We explored anti-PCa activity in a polyphenol-rich fraction of Bergenia ligulata (PFBL), a plant used in Indian traditional and folk medicine for its anti-inflammatory and antineoplastic properties. PFBL constituted of about fifteen different compounds as per LCMS analysis induced apoptotic death in both androgen-dependent LNCaP and androgen-refractory PC3 and DU145 cells with little effect on NKE and WI38 cells. Further investigation revealed that PFBL mediates its function through upregulating ROS production by enhanced catalytic activity of Monoamine oxidase A (MAO-A). Notably, the differential inactivation of NRF2-antioxidant response pathway by PFBL resulted in death in PC3 versus NKE cells involving GSK-3β activity facilitated by AKT inhibition. PFBL efficiently reduced the PC3-tumor xenograft in NOD-SCID mice alone and in synergy with Paclitaxel. Tumor tissues in PFBL-treated mice showed upregulation of similar mechanism of cell death as observed in isolated PC3 cells i.e., elevation of MAO-A catalytic activity, ROS production accompanied by activation of β-TrCP-GSK-3β axis of NRF2 degradation. Blood counts, liver, and splenocyte sensitivity analyses justified the PFBL safety in the healthy mice. To our knowledge this is the first report of an activity that crippled NRF2 activation both in vitro and in vivo in response to MAO-A activation. Results of this study suggest the development of a novel treatment protocol utilizing PFBL to improve therapeutic outcome for patients with aggressive PCa which claims hundreds of thousands of lives each year.

Item Type: Article
Subjects: Cancer Biology
Depositing User: Mr. Rameshwar Nema
Date Deposited: 24 Nov 2021 07:34
Last Modified: 24 Nov 2021 07:34
URI: http://nccs.sciencecentral.in/id/eprint/1067

Actions (login required)

View Item View Item